

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

SNU-216

RRID:CVCL_3946

Type: Cell Line

Proper Citation

RRID:CVCL_3946

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3946

Proper Citation: RRID:CVCL_3946

Description: Cell line SNU-216 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Gastric tubular adenocarcinoma

Defining Citation: [PMID:9033653](#), [PMID:15723654](#), [PMID:19956504](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25343454](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-216

Synonyms: SNU216, NCI-SNU-216

Cross References: BTO:BTO_0004988, EFO:EFO_0006754, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03473182, BioSample:SAMN10988071, cancercellines:CVCL_3946, Cell_Model_Passport:SIDM01393, CGH-DB:124-1, CGH-DB:9012-4, CLS:305630, Cosmic:685589, Cosmic:848139, Cosmic:1067205, Cosmic:1090453, Cosmic:1151969, Cosmic:1528874, Cosmic:2484970, DepMap:ACH-000466, EGA:EGAS00001000610, GEO:GSM887617, GEO:GSM888701, GEO:GSM1374887, IARC_TP53:7418,

KCLB:00216, LiGeA:CCL_434, PharmacDB:SNU216_1451_2019,
Progenetix:CVCL_3946, Wikidata:Q54955148

ID: CVCL_3946

Record Creation Time: 20220427T221551+0000

Record Last Update: 20260920T005805+0000

Ratings and Alerts

No rating or validation information has been found for SNU-216.

No alerts have been found for SNU-216.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kang M, et al. (2026) Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. *Molecular cancer therapeutics*, 25(5), 814.

He J, et al. (2026) UBE2B Drives NF- κ B Signaling and Gastric Cancer Progression through BIRC2-Mediated K63-Linked Ubiquitination of TRAF1. *Molecular cancer research : MCR*, 24(6), 487.

Kim B, et al. (2024) Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. *Cancer medicine*, 13(16), e70104.

Peng Y, et al. (2024) Helicobacter pylori CagA-mediated ether lipid biosynthesis promotes ferroptosis susceptibility in gastric cancer. *Experimental & molecular medicine*, 56(2), 441.

Liang B, et al. (2024) Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer. *Cancer letters*, 587, 216702.

Chen S, et al. (2024) Anchoring of hyaluronan glycocalyx to CD44 reduces sensitivity of HER2-positive gastric cancer cells to trastuzumab. *The FEBS journal*.

Park J, et al. (2023) Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer. *Scientific reports*, 13(1), 22648.

Hu X, et al. (2023) Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. *Cancer communications (London, England)*, 43(8), 909.

Nargund AM, et al. (2022) Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. *Cancer research*, 82(14), 2538.

Sakai H, et al. (2021) Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. *Clinical and translational medicine*, 11(6), e454.

Seo EH, et al. (2020) ONECUT2 upregulation is associated with CpG hypomethylation at promoter-proximal DNA in gastric cancer and triggers ACSL5. *International journal of cancer*, 146(12), 3354.